Ocugen Inc (OCGN)

$1.39 +0.01 (0.72%)
Market Cap 467.16M
Revenue (ttm) 4.41M
Net Income (ttm) -67.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,538.55%
Debt to Equity Ratio 5.03
Volume 6,544,400
Avg Vol 7,076,822
Day's Range N/A - N/A
Shares Out 338.52M
Stochastic %K 74%
Beta 2.19
Analysts Strong Sell
Price Target $11.43

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484-328-4701
Address:
11 Great Valley Parkway, Malvern, United States
JuanGooo
JuanGooo Jun. 25 at 12:34 AM
$OCGN 🤔
1 · Reply
Kickstarterx10
Kickstarterx10 Jun. 25 at 12:14 AM
$OCGN
0 · Reply
Kickstarterx10
Kickstarterx10 Jun. 24 at 11:49 PM
$OCGN
0 · Reply
Djtrush
Djtrush Jun. 24 at 10:26 PM
$OCGN
0 · Reply
WayLoSellHi
WayLoSellHi Jun. 24 at 8:46 PM
$OCGN Green week still intact in 7 days we set the clock to Q3/H2 Ocufam which should induce several catalyst that propells us to better 💲days💲
0 · Reply
nick2341
nick2341 Jun. 24 at 8:16 PM
$OCGN if we follow Europe, the numbers always stick up. Sad we lost it to a lot of bears 🐻
0 · Reply
ColdSmkskier
ColdSmkskier Jun. 24 at 7:52 PM
$OCGN Global Pharma 1000%
0 · Reply
giglio75
giglio75 Jun. 24 at 7:47 PM
$OCGN will pass 10 millions shares at 15:59:59
1 · Reply
MaesTechnicalAnalysis
MaesTechnicalAnalysis Jun. 24 at 7:30 PM
$OCGN was on a downtrend, broke out of its resistances, keeping an eye out for 1.60+ https://youtu.be/xYsGw5Hsq_Q?is=TING9fmGzMbqd4li
1 · Reply
Lights1980
Lights1980 Jun. 24 at 7:29 PM
$OCGN last half hour, I would love to see a push to $1.45 to be near high of day. Also would love to see another 1 millionnin share volume.
0 · Reply
Latest News on OCGN
Ocugen Transcript: AGM 2026

Jun 11, 2026, 8:00 AM EDT - 13 days ago

Ocugen Transcript: AGM 2026

Ocugen Transcript: Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Jun 4, 2026, 2:30 PM EDT - 20 days ago

Ocugen Transcript: Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Jun 2, 2026, 7:03 AM EDT - 22 days ago

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Ocugen price target lowered to $11 from $12 at Canaccord

2026-05-27T11:37:17.000Z - 4 weeks ago

Ocugen price target lowered to $11 from $12 at Canaccord

Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 10:30 AM EDT - 4 weeks ago

Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

May 14, 2026, 4:30 PM EDT - 5 weeks ago

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

May 13, 2026, 7:02 AM EDT - 6 weeks ago

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

Ocugen reports Q1 EPS (6c), consensus (5c)

2026-05-05T13:15:52.000Z - 7 weeks ago

Ocugen reports Q1 EPS (6c), consensus (5c)

Ocugen Provides Business Update with First Quarter 2026 Financial Results

May 5, 2026, 8:32 AM EDT - 7 weeks ago

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 7 weeks ago

Ocugen Earnings Call Transcript: Q1 2026

Ocugen Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 7 weeks ago

Ocugen Earnings release: Q1 2026

Ocugen Quarterly report: Q1 2026

May 5, 2026, 8:30 AM EDT - 7 weeks ago

Ocugen Quarterly report: Q1 2026

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

May 5, 2026, 8:12 AM EDT - 7 weeks ago

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen announces private offering of $115M of convertible senior notes

2026-05-04T20:16:05.000Z - 7 weeks ago

Ocugen announces private offering of $115M of convertible senior notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

May 4, 2026, 4:01 PM EDT - 7 weeks ago

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Apr 29, 2026, 7:02 AM EDT - 2 months ago

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Ocugen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Ocugen Proxy statement: Proxy filing

Ocugen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Ocugen Proxy statement: Proxy filing

Ocugen to Present at April 2026 Investor and Industry Conferences

Apr 23, 2026, 7:02 AM EDT - 2 months ago

Ocugen to Present at April 2026 Investor and Industry Conferences

Ocugen Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Ocugen Proxy statement: Proxy filing

Ocugen Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Ocugen Proxy statement: Proxy filing

Ocugen completes dosing in GARDian3 trial

2026-04-01T11:56:15.000Z - 3 months ago

Ocugen completes dosing in GARDian3 trial

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Apr 1, 2026, 7:02 AM EDT - 3 months ago

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Ocugen price target raised to $12 from $8 at Noble Capital

2026-03-25T13:20:15.000Z - 3 months ago

Ocugen price target raised to $12 from $8 at Noble Capital

Ocugen price target raised to $10 from $7 at H.C. Wainwright

2026-03-25T10:11:21.000Z - 3 months ago

Ocugen price target raised to $10 from $7 at H.C. Wainwright

Ocugen Transcript: Study update

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Ocugen Transcript: Study update

Ocugen Press release: Study update

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Ocugen Press release: Study update

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

2026-03-24T11:55:27.000Z - 3 months ago

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Mar 24, 2026, 7:45 AM EDT - 3 months ago

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Mar 23, 2026, 7:02 AM EDT - 3 months ago

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Ocugen initiated with a Buy at Canaccord

2026-03-17T11:30:27.000Z - 3 months ago

Ocugen initiated with a Buy at Canaccord

Ocugen initiated with an Outperform at Oppenheimer

2026-03-11T10:40:53.000Z - 3 months ago

Ocugen initiated with an Outperform at Oppenheimer

Ocugen price target raised to $22 from $15 at Lucid Capital

2026-03-11T10:10:53.000Z - 3 months ago

Ocugen price target raised to $22 from $15 at Lucid Capital

Ocugen Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 4 months ago

Ocugen Earnings Call Transcript: Q4 2025

Ocugen Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 4 months ago

Ocugen Annual report: Q4 2025

Ocugen Earnings release: Q4 2025

Mar 4, 2026, 8:30 AM EST - 4 months ago

Ocugen Earnings release: Q4 2025

Ocugen reports Q4 EPS (6c), consensus (6c)

2026-03-04T13:28:15.000Z - 4 months ago

Ocugen reports Q4 EPS (6c), consensus (6c)

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 8:15 AM EST - 4 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete

2026-03-02T12:34:12.000Z - 4 months ago

Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Mar 2, 2026, 7:02 AM EST - 4 months ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Feb 9, 2026, 7:02 AM EST - 4 months ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 23, 2026, 8:00 AM EST - 5 months ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 21, 2026, 8:32 AM EST - 5 months ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Ocugen Transcript: Study result

Jan 15, 2026, 8:30 AM EST - 5 months ago

Ocugen Transcript: Study result

Ocugen Press release: Study result

Jan 15, 2026, 8:30 AM EST - 5 months ago

Ocugen Press release: Study result

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 15, 2026, 8:15 AM EST - 5 months ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 13, 2026, 7:00 AM EST - 5 months ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 12, 2026, 6:30 AM EST - 5 months ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Jan 9, 2026, 7:02 AM EST - 5 months ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 10, 2025, 9:20 AM EST - 7 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 20, 2025, 7:02 AM EST - 7 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Ocugen Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 8 months ago

Ocugen Earnings Call Transcript: Q3 2025

Ocugen Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 8 months ago

Ocugen Quarterly report: Q3 2025

Ocugen Earnings release: Q3 2025

Nov 5, 2025, 8:30 AM EST - 8 months ago

Ocugen Earnings release: Q3 2025

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Nov 5, 2025, 6:30 AM EST - 8 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 8 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Sep 25, 2025, 9:30 AM EDT - 9 months ago

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 15, 2025, 6:03 AM EDT - 10 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Sep 2, 2025, 7:02 AM EDT - 10 months ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 13, 2025, 6:27 AM EDT - 11 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 12, 2025, 3:45 PM EDT - 11 months ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 11 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen Earnings Call Transcript: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 11 months ago

Ocugen Earnings Call Transcript: Q2 2025

Ocugen Quarterly report: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 11 months ago

Ocugen Quarterly report: Q2 2025

Ocugen Earnings release: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 11 months ago

Ocugen Earnings release: Q2 2025

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Aug 1, 2025, 8:25 AM EDT - 11 months ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 21, 2025, 7:30 AM EDT - 1 year ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 18, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jul 17, 2025, 6:30 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 23, 2025, 7:30 AM EDT - 1 year ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 16, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

Jun 11, 2025, 7:30 AM EDT - 1 year ago

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Jun 5, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025, 7:02 AM EDT - 1 year ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q1 2025

Ocugen Quarterly report: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Quarterly report: Q1 2025

Ocugen Earnings release: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings release: Q1 2025

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025, 8:01 AM EDT - 1 year ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Ocugen Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Apr 8, 2025, 8:02 AM EDT - 1 year ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings Call Transcript: Q4 2024

Ocugen Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Annual report: Q4 2024

Ocugen Earnings release: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings release: Q4 2024

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 27, 2025, 8:46 AM EST - 1 year ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 8:00 AM EST - 1 year ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 12, 2025, 7:42 AM EST - 1 year ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Feb 3, 2025, 6:30 AM EST - 1 year ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen Registration statement: Registration Filing

Jan 31, 2025, 7:00 AM EST - 1 year ago

Ocugen Registration statement: Registration Filing

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 27, 2025, 6:30 AM EST - 1 year ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Jan 16, 2025, 7:30 AM EST - 1 year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

JuanGooo
JuanGooo Jun. 25 at 12:34 AM
$OCGN 🤔
1 · Reply
Kickstarterx10
Kickstarterx10 Jun. 25 at 12:14 AM
$OCGN
0 · Reply
Kickstarterx10
Kickstarterx10 Jun. 24 at 11:49 PM
$OCGN
0 · Reply
Djtrush
Djtrush Jun. 24 at 10:26 PM
$OCGN
0 · Reply
WayLoSellHi
WayLoSellHi Jun. 24 at 8:46 PM
$OCGN Green week still intact in 7 days we set the clock to Q3/H2 Ocufam which should induce several catalyst that propells us to better 💲days💲
0 · Reply
nick2341
nick2341 Jun. 24 at 8:16 PM
$OCGN if we follow Europe, the numbers always stick up. Sad we lost it to a lot of bears 🐻
0 · Reply
ColdSmkskier
ColdSmkskier Jun. 24 at 7:52 PM
$OCGN Global Pharma 1000%
0 · Reply
giglio75
giglio75 Jun. 24 at 7:47 PM
$OCGN will pass 10 millions shares at 15:59:59
1 · Reply
MaesTechnicalAnalysis
MaesTechnicalAnalysis Jun. 24 at 7:30 PM
$OCGN was on a downtrend, broke out of its resistances, keeping an eye out for 1.60+ https://youtu.be/xYsGw5Hsq_Q?is=TING9fmGzMbqd4li
1 · Reply
Lights1980
Lights1980 Jun. 24 at 7:29 PM
$OCGN last half hour, I would love to see a push to $1.45 to be near high of day. Also would love to see another 1 millionnin share volume.
0 · Reply
TheUrbanFarmer
TheUrbanFarmer Jun. 24 at 7:23 PM
$OCGN because remember. 😉🍻
4 · Reply
realwatcher
realwatcher Jun. 24 at 7:11 PM
$OCGN
1 · Reply
realwatcher
realwatcher Jun. 24 at 7:11 PM
$OCGN
0 · Reply
CaMeL036
CaMeL036 Jun. 24 at 6:43 PM
$OCGN
0 · Reply
sidsai
sidsai Jun. 24 at 6:39 PM
$OCGN market is red but xbi labu ocgn r green. Biotech looks good today.
0 · Reply
Norzepect
Norzepect Jun. 24 at 6:33 PM
$OCGN it’s nice to see green on low volume 
0 · Reply
Gr8peApe
Gr8peApe Jun. 24 at 6:17 PM
$OCGN
0 · Reply
Raith
Raith Jun. 24 at 6:16 PM
$OCGN It should be much higher. People being afraid to buy might cause them to reverse split. That would be a shame. $11 to $22 current evaluations
0 · Reply
Fox1Fox2
Fox1Fox2 Jun. 24 at 6:07 PM
$OCGN Connieeeeeeeeeeeeeeeeeeeeee !!!!!!
0 · Reply
Tomassso
Tomassso Jun. 24 at 6:06 PM
$OCGN Shankar and Ocugen working alongside the Gates Fundation and this is only going a few cents? Imsane
2 · Reply
RickLafleur
RickLafleur Jun. 24 at 6:02 PM
$OCGN The only green in a sea of red mess.
0 · Reply
BullishRaidTrendTracker
BullishRaidTrendTracker Jun. 24 at 5:58 PM
$OCGN Keeping an eye out for Ocugen for potential move to 2.00, currently moving above 200ma, a sign of reversal, https://x.com/hhuynhs/status/2069842509732393175
0 · Reply